Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) EPS (Weighted Average and Diluted): 2020-2024

Historic EPS (Weighted Average and Diluted) for vTv Therapeutics (VTVT) over the last 5 years, with Dec 2024 value amounting to -$3.20.

  • vTv Therapeutics' EPS (Weighted Average and Diluted) fell 22.73% to -$1.08 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.27, marking a year-over-year increase of 27.81%. This contributed to the annual value of -$3.20 for FY2024, which is 67.04% up from last year.
  • As of FY2024, vTv Therapeutics' EPS (Weighted Average and Diluted) stood at -$3.20, which was up 67.04% from -$9.71 recorded in FY2023.
  • Over the past 5 years, vTv Therapeutics' EPS (Weighted Average and Diluted) peaked at -$0.18 during FY2020, and registered a low of -$9.98 during FY2022.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$9.71 (2023), whereas its average is -$7.63.
  • Per our database at Business Quant, vTv Therapeutics' EPS (Weighted Average and Diluted) plummeted by 4,505.56% in 2021 and then skyrocketed by 67.04% in 2024.
  • Over the past 5 years, vTv Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$0.18 in 2020, then tumbled by 4,505.56% to -$8.29 in 2021, then fell by 20.39% to -$9.98 in 2022, then increased by 2.71% to -$9.71 in 2023, then skyrocketed by 67.04% to -$3.20 in 2024.